PCSK9-Hemmung – ein Update View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2022-04-21

AUTHORS

Julius L. Katzmann, Florian Custodis, Stephan H. Schirmer, Ulrich Laufs

ABSTRACT

Lowering of low-density lipoprotein (LDL) cholesterol represents one of the most effective interventions in cardiovascular prevention. Besides the oral treatment with statins, ezetimibe and bempedoic acid, subcutaneously administered inhibitors of proprotein convertase subtilisin-kexin type 9 (PCSK9) have been established as further cornerstones of lipid-lowering treatment. The antibodies evolocumab and alirocumab are administered subcutaneously every 2–4 weeks and lower LDL cholesterol by around 60%, independent of pre-treatment with very good tolerability. Both drugs successfully reduced cardiovascular endpoints in large outcome trials. A novel principle of PCSK9 inhibition is RNA interference, which is exploited by the novel compound inclisiran. Inclisiran is a double-stranded modified RNA molecule, which neutralizes the mRNA of PCSK9 and thus inhibits PCSK9 protein synthesis intracellularly. Inclisiran only needs to be administered every 6 months. The cardiovascular outcome trial ORION‑4 is currently ongoing. In Germany, prescription of PCSK9 inhibitors is regulated by the decision of the Federal Joint Committee. Novel strategies to inhibit PCSK9 function are under development and include orally available drugs and animal experiment concepts on gene editing, which are in different states of evaluation. More... »

PAGES

196-203

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00059-022-05112-y

DOI

http://dx.doi.org/10.1007/s00059-022-05112-y

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1147286898

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/35445838


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1101", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical Biochemistry and Metabolomics", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Animals", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Anticholesteremic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cholesterol, LDL", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Ezetimibe", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "PCSK9 Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Proprotein Convertase 9", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Klinik und Poliklinik f\u00fcr Kardiologie, Universit\u00e4tsklinikum Leipzig, Liebigstra\u00dfe\u00a020, 04103, Leipzig, Deutschland", 
          "id": "http://www.grid.ac/institutes/grid.411339.d", 
          "name": [
            "Klinik und Poliklinik f\u00fcr Kardiologie, Universit\u00e4tsklinikum Leipzig, Liebigstra\u00dfe\u00a020, 04103, Leipzig, Deutschland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Katzmann", 
        "givenName": "Julius L.", 
        "id": "sg:person.012772401232.32", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012772401232.32"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Klinik f\u00fcr Innere Medizin II, Klinikum Saarbr\u00fccken, Saarbr\u00fccken, Deutschland", 
          "id": "http://www.grid.ac/institutes/grid.419839.e", 
          "name": [
            "Klinik f\u00fcr Innere Medizin II, Klinikum Saarbr\u00fccken, Saarbr\u00fccken, Deutschland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Custodis", 
        "givenName": "Florian", 
        "id": "sg:person.01354722427.72", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01354722427.72"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Klinik f\u00fcr Innere Medizin III, Universit\u00e4t des Saarlandes, Homburg/Saar, Deutschland", 
          "id": "http://www.grid.ac/institutes/grid.11749.3a", 
          "name": [
            "Kardiopraxis Schirmer, Kaiserslautern, Deutschland", 
            "Klinik f\u00fcr Innere Medizin III, Universit\u00e4t des Saarlandes, Homburg/Saar, Deutschland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Schirmer", 
        "givenName": "Stephan H.", 
        "id": "sg:person.01237506463.90", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01237506463.90"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Klinik und Poliklinik f\u00fcr Kardiologie, Universit\u00e4tsklinikum Leipzig, Liebigstra\u00dfe\u00a020, 04103, Leipzig, Deutschland", 
          "id": "http://www.grid.ac/institutes/grid.411339.d", 
          "name": [
            "Klinik und Poliklinik f\u00fcr Kardiologie, Universit\u00e4tsklinikum Leipzig, Liebigstra\u00dfe\u00a020, 04103, Leipzig, Deutschland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Laufs", 
        "givenName": "Ulrich", 
        "id": "sg:person.01316611454.23", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01316611454.23"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s40801-019-0158-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1117800293", 
          "https://doi.org/10.1007/s40801-019-0158-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/ng1161", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011528564", 
          "https://doi.org/10.1038/ng1161"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/s41586-021-03534-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1138172330", 
          "https://doi.org/10.1038/s41586-021-03534-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/d41573-021-00195-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1142692215", 
          "https://doi.org/10.1038/d41573-021-00195-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/s41569-018-0107-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1109811541", 
          "https://doi.org/10.1038/s41569-018-0107-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00395-017-0619-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1085050539", 
          "https://doi.org/10.1007/s00395-017-0619-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11883-020-00847-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1128192824", 
          "https://doi.org/10.1007/s11883-020-00847-7"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2022-04-21", 
    "datePublishedReg": "2022-04-21", 
    "description": "Lowering of low-density lipoprotein (LDL) cholesterol represents one of the most effective interventions in cardiovascular prevention. Besides the oral treatment with statins, ezetimibe and bempedoic acid, subcutaneously administered inhibitors of proprotein convertase subtilisin-kexin type\u00a09 (PCSK9) have been established as further cornerstones of lipid-lowering treatment. The antibodies evolocumab and alirocumab are administered subcutaneously every 2\u20134 weeks and lower LDL cholesterol by around 60%, independent of pre-treatment with very good tolerability. Both drugs successfully reduced cardiovascular endpoints in large outcome trials. A\u00a0novel principle of PCSK9 inhibition is RNA interference, which is exploited by the novel compound inclisiran. Inclisiran is a\u00a0double-stranded modified RNA molecule, which neutralizes the mRNA of PCSK9 and thus inhibits PCSK9 protein synthesis intracellularly. Inclisiran only needs to be administered every 6\u00a0months. The cardiovascular outcome trial ORION\u20114 is currently ongoing. In Germany, prescription of PCSK9 inhibitors is regulated by the decision of the Federal Joint Committee. Novel strategies to inhibit PCSK9 function are under development and include orally available drugs and animal experiment concepts on gene editing, which are in different states of evaluation.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00059-022-05112-y", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1087175", 
        "issn": [
          "0340-9937", 
          "1615-6692"
        ], 
        "name": "Herz", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "47"
      }
    ], 
    "keywords": [
      "proprotein convertase subtilisin kexin type", 
      "low-density lipoprotein cholesterol", 
      "lipid-lowering treatment", 
      "lower LDL cholesterol", 
      "large outcome trials", 
      "Federal Joint Committee", 
      "lipoprotein cholesterol", 
      "cardiovascular prevention", 
      "outcome trials", 
      "PCSK9 inhibition", 
      "PCSK9 inhibitors", 
      "oral treatment", 
      "good tolerability", 
      "cardiovascular endpoints", 
      "LDL cholesterol", 
      "bempedoic acid", 
      "available drugs", 
      "Joint Committee", 
      "PCSK9 function", 
      "inclisiran", 
      "ein Update", 
      "effective interventions", 
      "cholesterol", 
      "drugs", 
      "treatment", 
      "inhibitors", 
      "RNA interference", 
      "protein synthesis", 
      "novel strategy", 
      "alirocumab", 
      "tolerability", 
      "statins", 
      "ezetimibe", 
      "PCSK9", 
      "trials", 
      "weeks", 
      "endpoint", 
      "prevention", 
      "antibodies", 
      "months", 
      "intervention", 
      "prescription", 
      "inhibition", 
      "mRNA", 
      "cornerstone", 
      "Committee", 
      "evaluation", 
      "gene editing", 
      "update", 
      "RNA molecules", 
      "acid", 
      "function", 
      "strategies", 
      "development", 
      "types", 
      "novel principle", 
      "molecules", 
      "decisions", 
      "Germany", 
      "different states", 
      "synthesis", 
      "further cornerstone", 
      "interference", 
      "state", 
      "editing", 
      "principles", 
      "concept", 
      "experiment concept"
    ], 
    "name": "PCSK9-Hemmung \u2013 ein Update", 
    "pagination": "196-203", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1147286898"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00059-022-05112-y"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "35445838"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00059-022-05112-y", 
      "https://app.dimensions.ai/details/publication/pub.1147286898"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-10-01T06:50", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/article/article_944.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00059-022-05112-y"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00059-022-05112-y'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00059-022-05112-y'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00059-022-05112-y'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00059-022-05112-y'


 

This table displays all metadata directly associated to this object as RDF triples.

213 TRIPLES      21 PREDICATES      107 URIs      92 LITERALS      14 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00059-022-05112-y schema:about N1709ee195761487dbc2d6c5d6817b377
2 N2affbd62130b4612906c418ddfed01f5
3 N98e232ec690b430e96629b8c8a977d37
4 Naf6850f9bf34434696883d361077c41b
5 Nb56e2ddc57534787bfa902df925033c2
6 Ndabc89f505dc4c64ac1113c87c391c40
7 Nfa3374d9e98b420b8ebbe4e0dcf3a083
8 anzsrc-for:11
9 anzsrc-for:1101
10 schema:author Nab8e6832002d43d7904dfb7a6d388b7d
11 schema:citation sg:pub.10.1007/s00395-017-0619-0
12 sg:pub.10.1007/s11883-020-00847-7
13 sg:pub.10.1007/s40801-019-0158-0
14 sg:pub.10.1038/d41573-021-00195-4
15 sg:pub.10.1038/ng1161
16 sg:pub.10.1038/s41569-018-0107-8
17 sg:pub.10.1038/s41586-021-03534-y
18 schema:datePublished 2022-04-21
19 schema:datePublishedReg 2022-04-21
20 schema:description Lowering of low-density lipoprotein (LDL) cholesterol represents one of the most effective interventions in cardiovascular prevention. Besides the oral treatment with statins, ezetimibe and bempedoic acid, subcutaneously administered inhibitors of proprotein convertase subtilisin-kexin type 9 (PCSK9) have been established as further cornerstones of lipid-lowering treatment. The antibodies evolocumab and alirocumab are administered subcutaneously every 2–4 weeks and lower LDL cholesterol by around 60%, independent of pre-treatment with very good tolerability. Both drugs successfully reduced cardiovascular endpoints in large outcome trials. A novel principle of PCSK9 inhibition is RNA interference, which is exploited by the novel compound inclisiran. Inclisiran is a double-stranded modified RNA molecule, which neutralizes the mRNA of PCSK9 and thus inhibits PCSK9 protein synthesis intracellularly. Inclisiran only needs to be administered every 6 months. The cardiovascular outcome trial ORION‑4 is currently ongoing. In Germany, prescription of PCSK9 inhibitors is regulated by the decision of the Federal Joint Committee. Novel strategies to inhibit PCSK9 function are under development and include orally available drugs and animal experiment concepts on gene editing, which are in different states of evaluation.
21 schema:genre article
22 schema:isAccessibleForFree false
23 schema:isPartOf N3db9ef713bcf4de6be367043df0c0b4f
24 Na1f9494834114824b9781ae9863b0ac8
25 sg:journal.1087175
26 schema:keywords Committee
27 Federal Joint Committee
28 Germany
29 Joint Committee
30 LDL cholesterol
31 PCSK9
32 PCSK9 function
33 PCSK9 inhibition
34 PCSK9 inhibitors
35 RNA interference
36 RNA molecules
37 acid
38 alirocumab
39 antibodies
40 available drugs
41 bempedoic acid
42 cardiovascular endpoints
43 cardiovascular prevention
44 cholesterol
45 concept
46 cornerstone
47 decisions
48 development
49 different states
50 drugs
51 editing
52 effective interventions
53 ein Update
54 endpoint
55 evaluation
56 experiment concept
57 ezetimibe
58 function
59 further cornerstone
60 gene editing
61 good tolerability
62 inclisiran
63 inhibition
64 inhibitors
65 interference
66 intervention
67 large outcome trials
68 lipid-lowering treatment
69 lipoprotein cholesterol
70 low-density lipoprotein cholesterol
71 lower LDL cholesterol
72 mRNA
73 molecules
74 months
75 novel principle
76 novel strategy
77 oral treatment
78 outcome trials
79 prescription
80 prevention
81 principles
82 proprotein convertase subtilisin kexin type
83 protein synthesis
84 state
85 statins
86 strategies
87 synthesis
88 tolerability
89 treatment
90 trials
91 types
92 update
93 weeks
94 schema:name PCSK9-Hemmung – ein Update
95 schema:pagination 196-203
96 schema:productId N106e178c50984aa5b6b61f5ffbc6cf61
97 N7163cacc76254e81aabefdfe99df2f66
98 N8346afa28ea343ca8a5dc4bf7743e0fa
99 schema:sameAs https://app.dimensions.ai/details/publication/pub.1147286898
100 https://doi.org/10.1007/s00059-022-05112-y
101 schema:sdDatePublished 2022-10-01T06:50
102 schema:sdLicense https://scigraph.springernature.com/explorer/license/
103 schema:sdPublisher N579ae001dc614d4aa208ce6c78158df2
104 schema:url https://doi.org/10.1007/s00059-022-05112-y
105 sgo:license sg:explorer/license/
106 sgo:sdDataset articles
107 rdf:type schema:ScholarlyArticle
108 N106e178c50984aa5b6b61f5ffbc6cf61 schema:name pubmed_id
109 schema:value 35445838
110 rdf:type schema:PropertyValue
111 N1709ee195761487dbc2d6c5d6817b377 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
112 schema:name PCSK9 Inhibitors
113 rdf:type schema:DefinedTerm
114 N2affbd62130b4612906c418ddfed01f5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Humans
116 rdf:type schema:DefinedTerm
117 N3db9ef713bcf4de6be367043df0c0b4f schema:volumeNumber 47
118 rdf:type schema:PublicationVolume
119 N579ae001dc614d4aa208ce6c78158df2 schema:name Springer Nature - SN SciGraph project
120 rdf:type schema:Organization
121 N7163cacc76254e81aabefdfe99df2f66 schema:name dimensions_id
122 schema:value pub.1147286898
123 rdf:type schema:PropertyValue
124 N79c6bfc5252e4927a48e02e3146cb985 rdf:first sg:person.01237506463.90
125 rdf:rest Nde45eb30cb534d63a89dbd568f3808ae
126 N8346afa28ea343ca8a5dc4bf7743e0fa schema:name doi
127 schema:value 10.1007/s00059-022-05112-y
128 rdf:type schema:PropertyValue
129 N8cb2039c099046c4be80756a9ad15142 rdf:first sg:person.01354722427.72
130 rdf:rest N79c6bfc5252e4927a48e02e3146cb985
131 N98e232ec690b430e96629b8c8a977d37 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Cholesterol, LDL
133 rdf:type schema:DefinedTerm
134 Na1f9494834114824b9781ae9863b0ac8 schema:issueNumber 3
135 rdf:type schema:PublicationIssue
136 Nab8e6832002d43d7904dfb7a6d388b7d rdf:first sg:person.012772401232.32
137 rdf:rest N8cb2039c099046c4be80756a9ad15142
138 Naf6850f9bf34434696883d361077c41b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Proprotein Convertase 9
140 rdf:type schema:DefinedTerm
141 Nb56e2ddc57534787bfa902df925033c2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Animals
143 rdf:type schema:DefinedTerm
144 Ndabc89f505dc4c64ac1113c87c391c40 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Anticholesteremic Agents
146 rdf:type schema:DefinedTerm
147 Nde45eb30cb534d63a89dbd568f3808ae rdf:first sg:person.01316611454.23
148 rdf:rest rdf:nil
149 Nfa3374d9e98b420b8ebbe4e0dcf3a083 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Ezetimibe
151 rdf:type schema:DefinedTerm
152 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
153 schema:name Medical and Health Sciences
154 rdf:type schema:DefinedTerm
155 anzsrc-for:1101 schema:inDefinedTermSet anzsrc-for:
156 schema:name Medical Biochemistry and Metabolomics
157 rdf:type schema:DefinedTerm
158 sg:journal.1087175 schema:issn 0340-9937
159 1615-6692
160 schema:name Herz
161 schema:publisher Springer Nature
162 rdf:type schema:Periodical
163 sg:person.01237506463.90 schema:affiliation grid-institutes:grid.11749.3a
164 schema:familyName Schirmer
165 schema:givenName Stephan H.
166 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01237506463.90
167 rdf:type schema:Person
168 sg:person.012772401232.32 schema:affiliation grid-institutes:grid.411339.d
169 schema:familyName Katzmann
170 schema:givenName Julius L.
171 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012772401232.32
172 rdf:type schema:Person
173 sg:person.01316611454.23 schema:affiliation grid-institutes:grid.411339.d
174 schema:familyName Laufs
175 schema:givenName Ulrich
176 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01316611454.23
177 rdf:type schema:Person
178 sg:person.01354722427.72 schema:affiliation grid-institutes:grid.419839.e
179 schema:familyName Custodis
180 schema:givenName Florian
181 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01354722427.72
182 rdf:type schema:Person
183 sg:pub.10.1007/s00395-017-0619-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1085050539
184 https://doi.org/10.1007/s00395-017-0619-0
185 rdf:type schema:CreativeWork
186 sg:pub.10.1007/s11883-020-00847-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1128192824
187 https://doi.org/10.1007/s11883-020-00847-7
188 rdf:type schema:CreativeWork
189 sg:pub.10.1007/s40801-019-0158-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1117800293
190 https://doi.org/10.1007/s40801-019-0158-0
191 rdf:type schema:CreativeWork
192 sg:pub.10.1038/d41573-021-00195-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1142692215
193 https://doi.org/10.1038/d41573-021-00195-4
194 rdf:type schema:CreativeWork
195 sg:pub.10.1038/ng1161 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011528564
196 https://doi.org/10.1038/ng1161
197 rdf:type schema:CreativeWork
198 sg:pub.10.1038/s41569-018-0107-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1109811541
199 https://doi.org/10.1038/s41569-018-0107-8
200 rdf:type schema:CreativeWork
201 sg:pub.10.1038/s41586-021-03534-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1138172330
202 https://doi.org/10.1038/s41586-021-03534-y
203 rdf:type schema:CreativeWork
204 grid-institutes:grid.11749.3a schema:alternateName Klinik für Innere Medizin III, Universität des Saarlandes, Homburg/Saar, Deutschland
205 schema:name Kardiopraxis Schirmer, Kaiserslautern, Deutschland
206 Klinik für Innere Medizin III, Universität des Saarlandes, Homburg/Saar, Deutschland
207 rdf:type schema:Organization
208 grid-institutes:grid.411339.d schema:alternateName Klinik und Poliklinik für Kardiologie, Universitätsklinikum Leipzig, Liebigstraße 20, 04103, Leipzig, Deutschland
209 schema:name Klinik und Poliklinik für Kardiologie, Universitätsklinikum Leipzig, Liebigstraße 20, 04103, Leipzig, Deutschland
210 rdf:type schema:Organization
211 grid-institutes:grid.419839.e schema:alternateName Klinik für Innere Medizin II, Klinikum Saarbrücken, Saarbrücken, Deutschland
212 schema:name Klinik für Innere Medizin II, Klinikum Saarbrücken, Saarbrücken, Deutschland
213 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...